Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.
Pharmacogenomics
; 22(5): 263-274, 2021 04.
Article
en En
| MEDLINE
| ID: mdl-33657875
ABSTRACT
Aim:
To assess providers' knowledge, attitudes, perceptions, and experiences related to pharmacogenomic (PGx) testing in pediatric patients. Materials &methods:
An electronic survey was sent to multidisciplinary healthcare providers at a pediatric hospital.Results:
Of 261 respondents, 71.3% were slightly or not at all familiar with PGx, despite 50.2% reporting prior PGx education or training. Most providers, apart from psychiatry, perceived PGx to be at least moderately useful to inform clinical decisions. However, only 26.4% of providers had recent PGx testing experience. Unfamiliarity with PGx and uncertainty about the clinical value of testing were common perceived challenges.Conclusion:
Low PGx familiarity among pediatric providers suggests additional education and electronic resources are needed for PGx examples in which data support testing in children.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pediatría
/
Personal de Salud
/
Pruebas de Farmacogenómica
Tipo de estudio:
Prognostic_studies
/
Qualitative_research
Límite:
Humans
Idioma:
En
Revista:
Pharmacogenomics
Asunto de la revista:
FARMACOLOGIA
/
GENETICA MEDICA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos